Announcements
-
RFS Awards in Science Winner
Mary Ann Liebert, Inc., in partnership with the Rosalind Franklin Society launched a prestigious annual award to recognize outstanding published peer-reviewed research by women and underrepresented minorities in science in each of the publisher’s peer-reviewed journals. The RFS Awards in Science for Journal of Ocular Pharmacology and Therapeutics has selected Goldis Malek, PhD who co-authored Gene Delivery of a Caspase Activation and Recruitment Domain Improves Retinal Pigment Epithelial Function and Modulates Inflammation in a Mouse Model with Features of Dry Age-Related Macular Degeneration.
Aims & Scope
Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines ophthalmology and pharmacology to enable optimal treatment, prevention, and diagnosis of ocular diseases and disorders. It presents the latest in the ophthalmic drug discovery, delivery, and product development, emphasizing biopharmaceutics, pharmacokinetics, pharmacodynamics, and mechanisms of drug action.
Journal of Ocular Pharmacology and Therapeutics coverage includes:
- Drug discovery and development
- Mechanisms of drug action
- Drug delivery, nanomedicine, and nanotechnology
- Biopharmaceutics, pharmacokinetics, pharmacodynamics, and mathematical modeling
- Drug transporters and drug metabolism
- Pre-clinical and early-stage clinical trial results
- Gene and cell-based therapies
- Combination products
- Ocular pharmacotherapy/clinical trials/biomarkers
- Ocular toxicology and toxicokinetics
- Dry eye and ocular surface diseases
- Corneal diseases
- Glaucoma and optic neuropathies
- Retinal diseases
- Lens and cataract
- Ocular infection and trauma
- Ocular inflammatory and immune disorders
- Ocular ischemia and blood flow
- Ocular metabolic disorders
- Ocular pain
- Oculomotor complications
- Proliferative disorders of the eye
- Therapeutics for myopia and refractive errors
- Therapeutics for strabismus, ambylopia, and visual processing
- Eyes on New Product Development — written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA
Journal of Ocular Pharmacology and Therapeutics is under the editorial leadership of Uday B. Kompella, PhD, University of Colorado Anschutz Medical Campus; and his Associate Editors: Linda D. Hazlett, PhD, Wayne State University School of Medicine, Ocular Surface Pharmacology; Naj A. Sharif, PhD, FARVO, Santen Incorporated, Pre-clinical Ocular Pharmacology; Carol B. Toris, PhD, The Ohio State University Wexner Medical Center, Aqueous Humor Dynamics; and Oliver Zeitz, MD, Charité - University Medicine Berlin; and an editorial board of leading experts. View the entire editorial board.
Audience: Academic, industry, and government scientists, ophthalmologists, optometrists, clinical and research trainees, and many others
Indexing/Abstracting:
- PubMed/MEDLINE
- PubMed Central
- Current Contents®/Life Sciences
- Biological Abstracts
- BIOSIS Citation Index™
- Journal Citation Reports/Science Edition
- Prous Science Integrity®
- EMBASE/Excerpta Medica
- Scopus
- Chemical Abstracts
- ProQuest databases
- CAB Abstracts
- Global Health
- BenchSci
